GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosimilars,today announced the company has reached an exclusivecommercialization and license agreement with IntasPharmaceuticals for BAT2506, a golimum...
DetailsGUANGZHOU,China, October 24, 2023 -- Bio-Thera Solutions, Ltd (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of biosimilarsand innovative assets, announced that the National Health Surveillance Agency(“ANVISA”) published the approval of the certification of good m...
TOFIDENCE is Bio-Thera’s first productapproved by USFDA. TOFIDENCE is the first monoclonal antibodydrug researched, developed, and manufactured by a Chinese pharmaceuticalcompany to receive FDA approval in the United States TOFIDENCE is the first biosimilar toActemra approved by USFDA GUANGZHOU, C...
GUANGZHOU,China --(PR Newswire) -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceuticalcompany developing a pipeline of innovative and biosimilars, today announcedpositive Phase 1 clinical data for BAT8006 (Folate-Receptor-α-ADC) as part of apresentation of the clinical result...
